Clin Case Rep Int | Volume 3, Issue 1 | Case Report | Open Access
Ya-Wen Lu1* and Tsung-Chia Chen2
1Department of Pharmacy, Taichung Hospital, Taiwan 2Department of Internal Medicine, Taichung Hospital, TaiwanFulltext PDF
Case Report: A fixed dose of Trimethoprim-Sulfamethoxazole (TMP/SMZ) is the treatment of choice for Pneumocystis Jirovecii Pneumonia (PJP) recommended by Infectious Diseases Society of America (IDSA). However, TMP/SMZ has been reported to cause hemolysis when administered to patients with deficiency. PJP might be fatal without receiving treatment. Therefore, there is a dilemma on the use of TMP/SMZ in G6PD deficient patients. Herein, we report a G6PD deficient patient with PJP treated successfully with 21 days of TMP/SMZ without any signs and symptoms of hemolysis. Conclusion: It might be safe for the Southeast Asia population with a history of G6PD deficiency to administer TMP/SMZ under expert surveillance.
Glucose-6-phosphate dehydrogenase deficiency; HIV; Pneumocystis pneumonia; Trimethoprim-sulfamethoxazole
Lu Y-W, Chen T-C. Use of Trimethoprim-Sulfamethoxazole in Patient with G6PD Deficiency for Treating Pneumocystis Jirovecii Pneumonia. Clin Case Rep Int. 2019;3:1119.